Table of Contents Table of Contents
Previous Page  353 / 1138 Next Page
Information
Show Menu
Previous Page 353 / 1138 Next Page
Page Background

/

Matthias Guckenberger - DEGRO 2015

32

Dose de-escalation

Excellent OS of 20.4 months in Platinum-resistant

stage NSCLC DESPITE lower irradiation doses

Prospective Phase II trial

Iyenger JCO 2014

Maximum 5 Platin-resistant sites based on FDG-PET

SBRT to all progressive sites,

Switch to concurrent Erlotinib

24 patients with 52 sites

1 Fx

3 Fx

5 Fx

Physical

dose

19 – 24Gy 27 – 33Gy 35 – 40Gy

Max BED

82Gy

70Gy

72Gy

In-field failure

3 / 21

Out-field failure

10 / 21

No failure

10 / 21

29.08.2015